AG
BOLD

Artal Group’s Audentes Therapeutics, Inc BOLD Stock Holding History

Artal Group’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-350,000
Closed -$9.83M – 114
2019
Q3 		$9.83M Hold
350,000
– – 0.39% 49
2019
Q2 		$13.3M Sell
350,000
-50,000
-13% -$1.92M 0.54% 40
2019
Q1 		$15.6M Sell
400,000
-200,000
-33% -$5.73M 0.64% 36
2018
Q4 		$12.8M Buy
600,000
+350,000
+140% +$9.03M 0.47% 37
2018
Q3 		$9.9M Buy
250,000
+14,000
+6% +$522K 0.26% 55
2018
Q2 		$9.02M Buy
236,000
+86,000
+57% +$3.19M 0.19% 50
2018
Q1 		$4.51M Sell
150,000
-50,000
-25% -$1.69M 0.06% 76
2017
Q4 		$6.25M Hold
200,000
– – 0.09% 62
2017
Q3 		$5.6M Buy
+200,000
New +$4.34M 0.1% 59

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Artal Group's BOLD Position: Q4 2019 in Review

Artal Group sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 350,000 shares — an estimated $9.83M sold.

Artal Group first reported a position in BOLD in Q3 2017 and held it in 9 quarters. The position peaked at $15.6M in Q1 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Artal Group reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Artal Group sold 350,000 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $9.83M.
  • Artal Group first reported a position in Audentes Therapeutics, Inc in Q3 2017 and held it in 9 quarters.
  • Artal Group's Audentes Therapeutics, Inc position peaked at $15.6M in Q1 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Artal Group's 13F filing for Q4 2019, filed 13 Feb 2020.